TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06206291

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo twice daily for first 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo twice daily for first 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) 200mg
Description: First 4 weeks: CBD (200mg)/Placebo twice daily adjunct with opioid agonist treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) 200mg
Description: First 4 weeks: CBD (200mg)/Placebo twice daily adjunct with opioid agonist treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) 400mg
Description: Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol (CBD) 400mg
Description: Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) 400mg
Description: Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol (CBD) 400mg
Description: Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.
Study: NCT05322967

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time of ordinary antihypertensive medication intake
Description: Time of ordinary antihypertensive medication intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time of ordinary antihypertensive medication intake
Description: Time of ordinary antihypertensive medication intake
Study: NCT05779839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Algorithm
Description: For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be matched using an algorithm. They can then choose make a connection and maintain a connection for the duration of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Random Match
Description: For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be randomly matched. They can then choose make a connection and maintain a connection for the duration of the study.
Study: NCT05989867

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Evaluation of islets function and insulin secretion pattern： Evaluating the venous plasma glucose, c-peptide, and insulin concentrations at 0h, 0.5h, 1h, 2h, and 3h after the SBMT in patients with chronic pancreatitis.~Characterization of pathophysiological features： Measuring intestinal hormones, exosomes, serum metabolites, and serum biochemical factors

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Evaluation of islets function and insulin secretion pattern： Evaluating the venous plasma glucose, c-peptide, and insulin concentrations at 0h, 0.5h, 1h, 2h, and 3h after the SBMT in patients with chronic pancreatitis.~Characterization of pathophysiological features： Measuring intestinal hormones, exosomes, serum metabolites, and serum biochemical factors

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Evaluation of islets function and insulin secretion pattern： Evaluating the venous plasma glucose, c-peptide, and insulin concentrations at 0h, 0.5h, 1h, 2h, and 3h after the SBMT in patients with chronic pancreatitis.~Characterization of pathophysiological features： Measuring intestinal hormones, exosomes, serum metabolites, and serum biochemical factors

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Evaluation of islets function and insulin secretion pattern： Evaluating the venous plasma glucose, c-peptide, and insulin concentrations at 0h, 0.5h, 1h, 2h, and 3h after the SBMT in patients with chronic pancreatitis.~Characterization of pathophysiological features： Measuring intestinal hormones, exosomes, serum metabolites, and serum biochemical factors

Intervention type: DEVICE
Intervention: Continuous Glucose Monitor
Description: blood glucose will be monitored 24 hours a day from 7 to 14 days by wearing continuous glucose monitor(only for patients who had new-onset diabetes or poor glycemic control )

Intervention type: DEVICE
Intervention: Continuous Glucose Monitor
Description: blood glucose will be monitored 24 hours a day from 7 to 14 days by wearing continuous glucose monitor(only for patients who had new-onset diabetes or poor glycemic control )

Intervention type: DEVICE
Intervention: Continuous Glucose Monitor
Description: blood glucose will be monitored 24 hours a day from 7 to 14 days by wearing continuous glucose monitor(only for patients who had new-onset diabetes or poor glycemic control )
Study: NCT04373122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBOA
Description: Resuscitative Endovascular Balloon Occlusion of the Aorta
Study: NCT05117801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Petale
Description: The child sits on the companion's lap between the two enclosures, and the investigator observes whether or not he is attracted to a familiar calibrated noise coming from one side or the other.
Study: NCT00629213

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04821011

Intervention type: DEVICE
Intervention: electronic stethoscope
Description: Record of maternal heart sounds (heartbeats) with an electronic stethoscope during 10 minutes.

Intervention type: DEVICE
Intervention: acoustic listening of mother's heartbeats
Description: Each newborn included will have 20 minutes of an acoustic listening of their mother heartbeats previously recorded.

Intervention type: DEVICE
Intervention: Recording of the newborn's heart rate
Description: Recording of the newborn's heart rate: one hour before the acoustic listening, during the acoustic listening and one hour after the acoustic listening .~The variations of the autonomic nervous system will be analyzed.~An coupled Heart rate variability recording (ECG signal obtained from a Philips® IntelliVue MX700 monitor) and NIPΣ index of comfort (MDMS® NIPΣ monitor) will be used.
Study: NCT06302335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Description: Application of Povidone-iodine to the surgical wound of patients submitted to colorectal resections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: Application of saline solution to the surgical wound of patients submitted to colorectal resections.
Study: NCT06309758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breinzorg
Description: The BreinZorg multidomain lifestyle website comprises 16 domains, namely (1) physical activity, (2) healthy diet, (3) smoking, (4) alcohol, (5) sleep, (6) cognitive activity (7) social activity, (8) diabetes, (9) blood pressure, (10) cholesterol, (11) heart- and vascular diseases, (12) kidney diseases, (13) hearing damage, (14) obesity, (15) anxiety, and (16) depression. These 16 modules are separated into three big themes: mood, lifestyle, and body.~Each module consists of the following:~1. General information on the risk factor;~2. Tips on how to improve and decrease the risk;~3. Quiz questions about the risk factor, giving extra knowledge/ in a playful and interactive manner;~4. Examples of SMART goals fitting the risk factor (goal examples are given in a Specific, Measurable, Achievable, Relevant, and Time-Bound manner).
Study: NCT04747145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 60 Gy to be delivered over 30 daily treatments in six weeks. Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemotherapy (Temozolomide)
Description: 75mg/m\^2 x 42 days (concurrent chemotherapy with radiation). Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy (Temozolomide)
Description: Starting no sooner than 4 weeks after completion of chemoradiation, 150-200mg/m\^2, days 1-5 of 28-day cycle, for minimum of six cycles and up to 12 cycles.
Study: NCT05292365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RE-PACT Intervention
Description: * Create respiratory illness action plan~* Weekly mHealth text messages~* Monthly study assessments~* Action planning and JIT coaching
Study: NCT05815927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab: 400mg Q6W up to 2 years (i.e 17 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab: 400mg Q6W up to 2 years (i.e 17 cycles).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotattic ablation radiotherapy (SABR)
Description: Total dose and number of fractions will depend on the site of the disease. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.
Study: NCT05255757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Script Intervention
Description: This intervention provides language to participants to allow them to discuss kidney transplantation with their social network.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Script Intervention
Description: This intervention provides language to participants to allow them to discuss kidney transplantation with their social network.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search Intervention
Description: This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search Intervention
Description: This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.
Study: NCT05831085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: State-of-the-Art Percutaneous Coronary Intervention
Description: supported by intracoronary imaging (e.g., intravascular ultrasound \[IVUS\] or optical coherence tomography \[OCT\]), intracoronary physiology (e.g., fractional flow reserve \[FFR\] or instantaneous wave-free ratio \[iFR\]), contemporary metallic drug-eluting stents (DES), guideline-directed optimal medical therapy \[GDMT\] with advanced cardiovascular and anti-diabetic medications \[e.g., a sodium-glucose cotransporter \[SGLT\]-2 inhibitors\]) in patients with type 2 diabetes and three-vessel coronary artery disease (CAD) (not involving left main)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard CABG
Description: Coronary-Artery Bypass Grafting
Study: NCT05085002

Intervention type: DRUG
Group type: OTHER
Intervention: Lerociclib + Letrozole or Fulvestrant
Description: All participants (1L and 2L populations) will receive an AI (letrozole) or fulvestrant plus lerociclib 150 mg BID.
Study: NCT04690972

Intervention type: PROCEDURE
Intervention: Blood sample during surgery
Description: During the hepato-bilio-pancreatic surgery, blood is drawn.

Intervention type: PROCEDURE
Intervention: Taking an additional biopsy
Description: As part of the treatment, an additional biopsy is executed and blood is drawn.
Study: NCT05382715

Intervention type: DRUG
Intervention: Ozanimod
Description: Specified Dose on Specified Days
Study: NCT05591703

Intervention type: BEHAVIORAL
Intervention: Clinical Outcomes and Questionnaires
Description: Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.
Study: NCT04932889

Intervention type: OTHER
Intervention: Survey
Description: A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease...), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc..., treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.
Study: NCT04690972

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample during diagnostic test
Description: Blood sample as part of the care
Study: NCT04983368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanamem® 5 mg
Description: Oral Xanamem® (UE2343) capsules 5 mg, administered orally once daily.
Study: NCT04932889

Intervention type: OTHER
Intervention: Survey
Description: A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease...), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc..., treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.

Intervention type: OTHER
Intervention: Laboratory parameters
Description: The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.

Intervention type: OTHER
Intervention: Laboratory parameters
Description: The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.

Intervention type: OTHER
Intervention: chest computed tomography
Description: Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).

Intervention type: OTHER
Intervention: chest computed tomography
Description: Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).
Study: NCT05732129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: 150mg,orally, bid (days 1-7) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 30-90min continuous infusion 180mg/m2 Irinotecan on day 1, q2w
Study: NCT06261528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: Light therapy aimed at alleviating fatigue through circadian rhythm synchronization
Study: NCT06421324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health reccommendations
Description: Patients are given recommendations according to their risk group, based on the model which already predicted health indicators. This information will be sent to the patient's treating physician so that treatment and recommendations are aligned with the clinical care practice based on the European Code of Cancer guidelines, the H. pylori best practices guidelines and European GIM guidelines
Study: NCT04983368

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanamem® 10 mg
Description: Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily.
Study: NCT03952299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Transdermal Patch
Description: Transdermal patch of oxybutynin will be used instead of oral oxybutynin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Oxybutynin
Description: Oral administration of oxybutynin (5mg) every 8 hours in the hospital.
Study: NCT06246045

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Walking test
Description: PERT will be activated by AI algorithm. As a result of the discussion, patients will either be determined to be appropriate for immediate invasive strategy versus watchful waiting depending on whether high-risk PE criteria are met.~For those in the intermediate-high risk category, there remains ambiguity on timing and appropriateness of invasive intervention. On day 1 of admission, patients will undergo a walking test evaluating for abnormalities in heart rate, heart rate recovery, and oxygen need. If criteria is met, patients will be randomized in a 2:1 fashion (treatment versus control) to evaluate use of early-invasive strategy.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Walking test
Description: PERT will be activated by AI algorithm. As a result of the discussion, patients will either be determined to be appropriate for immediate invasive strategy versus watchful waiting depending on whether high-risk PE criteria are met.~For those in the intermediate-high risk category, there remains ambiguity on timing and appropriateness of invasive intervention. On day 1 of admission, patients will undergo a walking test evaluating for abnormalities in heart rate, heart rate recovery, and oxygen need. If criteria is met, patients will be randomized in a 2:1 fashion (treatment versus control) to evaluate use of early-invasive strategy.
Study: NCT05329194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Participants will be receiving subcutaneous injection of tezepelumab.
Study: NCT05702151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP Block
Description: After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed. Ropivacaine 0.2% infusion at a 10ml/h rate is started during the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine injection
Description: Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine injection
Description: Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
Study: NCT05537064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-visit Based Intervention
Description: At the beginning of the study period, PCPs will be sent an Inbasket message, a secure electronic messaging system included in EPIC, similar to an email. The message will notify them that pended orders for a referral to centralized pharmacy services for statin management will be entered for eligible patients unless the provider opts out. If no opt-out is received from the PCP within 7 days of receiving the message, their eligible patient panels will be referred to a centralized pharmacy team to begin pending referral orders to the PCP for eligible patients. Pharmacists affiliated with the centralized pharmacy service will then enter pended orders for referral to centralized pharmacy services that PCPs can sign either individually or in bulk. After the PCP signs the order for referral to centralized pharmacy services, a pharmacist from the centralized pharmacy team will then reach out to the patient on behalf of their PCP and discuss their indication for statin therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit-Based Intervention
Description: The study team will build an interruptive BestPractice advisory (BPA), a pop-up notification in the EHR that is delivered to the PCP when they open the patient's chart during a non-acute patient visit. The BestPractice Advisory will describe the guideline criteria for which the patient is eligible for statin therapy, and recommend referral to a centralized pharmacy service for statin initiation and management. It will also include a link to a menu for prescribing an appropriate-dose statin, should the PCP want to prescribe a statin without referral to pharmacy services. The option for ordering referral to centralized pharmacy services will be pre-selected, such that if the PCP simply clicks Accept on the BPA, an order for referral to centralized pharmacy services for statin initiation and management will be generated.
Study: NCT05290363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A 51 mL blood sample will be collected during the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A 51 mL blood sample will be collected during the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synovial aspiration
Description: If synovial aspiration is required in standard care for patients with peripheral spondylarthritis. Medical waste product will be collected for the study